article thumbnail

The digital transformation of pharma’s physician engagement strategies

pharmaphorum

In doing so it’s compounded pre-existing pressure with pharma, where schedules are shrinking and policies are often already restrictive enough to build barriers for effective physician engagement. The threat of disease spread and other risk factors from COVID-19 have only compounded this.

article thumbnail

Immuno-oncology market set to grow in billions, but access concerns remain

Pharmaceutical Technology

While the market was worth over $6 billion in 2012, this has now grown to nearly $48 billion only a decade later, said Avigayil Chalk, PhD, GlobalData’s Senior Oncology and Haematology analyst, at an immuno-oncology webinar held on May 23. This high compound annual growth rate of 23.6%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CDER’s Office of Compliance Kicks Off Annual Report Season with Rundown of 2023’s Major Public Health Enforcement Initiatives

The FDA Law Blog

Some takeaways on those efforts that we gleaned from the report: Compounding. OC devoted a lot of resources to its compliance efforts directed at human drug compounding. Communication in this area included on-line videos, webinars, summits, conferences, and international outreach. Drug Supply Chain.

article thumbnail

How Process Simulation Enhances Tech Transfer and Regulatory Submissions in the Biopharma Product Lifecycle

ISPE

For example, process simulators can report model-based air emissions such as volatile organic compounds (VOCs) with great accuracy since they are grounded in robust physical properties calculations, like activity coefficient models, that are embedded in the simulators. These calculations are then shared with the environmental agencies.

article thumbnail

Strategies for Streamlining Small Molecule Formulation Development When Bridging from Candidate Selection to First-in-Human Clinical Testing

Pharmaceutical Technology

At this stage, lead compounds will be ranked based on their activity in primary and secondary assays, demonstrating acceptable specificity and selectivity for the biological target that is proposed to be key for the desired therapeutic area. We start by using in-silico modeling of any pre-existing data associated with the lead compounds.

article thumbnail

How Digital Transformation Will Accelerate the Delivery of Culturally Competent Care by Pharmacists

Omnicell

I nefficient workflows and lack of data visibility compound Pharmacy challenges. Learn more about Dr. Rab’s perspective on the pharmacist’s role on the care team by viewing this recent webinar on how digital transformation frees pharmacists to provide culturally competent care to all patients.

article thumbnail

Unleash Pharmacy Transformation with Intelligent Infrastructure

Omnicell

Fewer than 15% of healthcare systems currently automate sterile compounding, yet in an average outpatient pharmacy, it is estimated that four medication errors occur every single day.